Drug-drug Interaction Study with GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects
An Open-label, Fixed-sequence Drug-drug Interaction Study in Healthy Subjects to Evaluate the Effect of GLPG4716 on the Pharmacokinetics of Nintedanib and Pirfenidone
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Neu-Ulm, Germany, 89231
- Nuvisan GmbH
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female between 18 and 55 years of age (extremes included), on the date of signing the informed consent form (ICF). Female subjects should be of non-childbearing potential.
- A body mass index (BMI) between 18.0 and 30.0 kg/m2, inclusive.
- Judged to be in good health by the investigator based upon the results of a medical history, physical examination, vital signs, electrocardiogram (ECG), and fasting clinical laboratory safety tests. Aspartate transaminase and alanine aminotransferase must be no greater than the upper limit of normal (ULN). Other clinical laboratory safety test results must be within the reference ranges or test results that are outside the reference ranges need to be considered not clinically significant in the opinion of the investigator
This list only includes the key inclusion criteria.
Exclusion Criteria:
- Known hypersensitivity to ingredients of GLPG4716, pirfenidone, or nintedanib or history of a significant allergic reaction to ingredients of GLPG4716, pirfenidone, or nintedanib as determined by the investigator.
- Treatment with any medication (including over-the-counter (OTC) and/or prescription medication, dietary supplements, nutraceuticals, vitamins and/or herbal supplements, and hormonal replacement therapy) except occasional paracetamol (maximum dose of 2 g/day and maximum of 10 g/2 weeks) in the last 2 weeks or 5 half-lives of the drug, whichever is longer, prior to the first dosing.
This list only includes the key exclusion criteria.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: GLPG4716 and pirfenidone
|
On Days 1 and 13, participants will receive an oral dose of pirfenidone.
From Day 3 to Day 14, participants will receive GLPG4716 daily.
|
|
Experimental: GLPG4716 and nintedanib
|
From Day 3 to Day 14, participants will receive GLPG4716 daily.
On Days 1 and 13, participants will receive an oral dose of nintedanib.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum observed plasma concentration (Cmax) of pirfenidone
Time Frame: From Day 1 pre-dose until Day 15
|
To determine the effect of GLPG4716 on the PK of pirfenidone
|
From Day 1 pre-dose until Day 15
|
|
Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) of pirfenidone
Time Frame: From Day 1 pre-dose until Day 15
|
To determine the effect of GLPG4716 on the PK of pirfenidone
|
From Day 1 pre-dose until Day 15
|
|
Cmax of nintedanib
Time Frame: From Day 1 pre-dose until Day 15
|
To determine the effect of GLPG4716 on the PK of nintedanib.
|
From Day 1 pre-dose until Day 15
|
|
AUC0-inf of nintedanib
Time Frame: From Day 1 pre-dose until Day 15
|
To determine the effect of GLPG4716 on the PK of nintedanib.
|
From Day 1 pre-dose until Day 15
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (SAEs), and TEAEs leading to treatment discontinuations.
Time Frame: From Day 1 through study completion, an average of 2 months
|
To evaluate the safety and tolerability of GLPG4716 alone or when co-administered with pirfenidone or nintedanib.
|
From Day 1 through study completion, an average of 2 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Natalia Rueda-Rincon, MD, Galapagos NV
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Pirfenidone
- Nintedanib
Other Study ID Numbers
Other Study ID Numbers
- GLPG4716-CL-101
- 2021-001718-12 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.